Eledon Pharmaceuticals (ELDN)
(Real Time Quote from BATS)
$2.72 USD
-0.11 (-3.89%)
Updated Jul 17, 2024 03:41 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ELDN 2.72 -0.11(-3.89%)
Will ELDN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELDN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELDN
Are Medical Stocks Lagging DaVita (DVA) This Year?
Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
ELDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy?
Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade
Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for ELDN
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Eledon Pharmaceuticals (ELDN) and Abbott Laboratories (ABT)